CTLA4 and inflammatory bowel disease: Nonetheless, anti–CTLA-4 therapy (odds ratio, 4.72; 95% CI, 0.95 to 23.53; P = .058) and IBD involving the colon (odds ratio, 3.61; 95% CI, 0.85 to 15.27; P = .081) showed tendency for an increased risk of GI adverse events (Table 5).